Communiqués Pharmadrug Inc.

Actions

PHRX

CA71716W2040

Produits pharmaceutiques

Marché Fermé - Canadian Securities Exchange 19:48:09 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,005000 ^CAD	0,00%		-50,00%	-66,67%

28/08	Pharmadrug Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2026	CI
28/05	Pharmadrug Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

13/05	PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus	NE
05/01	PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring	NE
03/11	PharmaDrug Announces Debt Restructuring	AQ
31/10/25	PharmaDrug Announces Debt Restructuring	NE
30/10/25	PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc	NE
30/07/25	PharmaDrug Inc.: Correction to News Release Dated July 30, 2025	NE
30/07/25	Canadian Investment Regulatory Organization Trading Halt - PHRX	AQ
30/07/25	PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.	NE
16/06/25	PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors	NE
06/06/25	PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value	NE
15/11/24	PharmaDrug Announces Issuance of Debenture Units	NE
31/10/24	PharmaDrug Announces Proposed Issuance of Debenture Units	NE
31/10/24	PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases	NE
19/09/24	PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases	NE
21/08/24	PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins	NE
19/08/24	PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine	NE
23/05/24	Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine	NE
15/05/24	PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine	NE
13/05/24	PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization	NE
02/05/24	PharmaDrug Announces Director Appointment and Resignation	NE
01/05/24	PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine	NE
16/04/24	PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine	NE
13/03/24	PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine	NE
27/02/24	PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman	NE
14/02/24	PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies	NE